ARWR
Arrowhead Pharmaceuticals Inc
61.50$
-0.1%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | -133.6% | – | -34.2% | +526.4% | -310.2% | – | |
| – | +10.5% | +6.1% | +5.7% | +5.1% | +4.2% | +16.2% | +2.3% | +2.6% | +0.1% | -0.3% | +4.6% | – | |
| – | +8.3% | -9.9% | -3.9% | +14.2% | -21.9% | +5.4% | -18.6% | +46.3% | +1.5% | -13.2% | -12.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -118.3% | – | +631.7% | -67.7% | -193.6% | – | -139.5% | – | – | – | -122.9% | – | |
| – | +7.4% | -50.4% | -57.6% | +68.1% | -69.1% | -29.5% | -55.4% | +216.8% | -71.3% | +19.4% | +50.3% | – | |
| – | +112.5% | -514.8% | – | -3,308.0% | – | -646.4% | – | -48.6% | -132.7% | +3,666.7% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | -7.4% | – | |
| – | – | – | – | – | – | – | -67.0% | – | -749.9% | – | -104.1% | – | |
| – | +75.7% | +161,239.7% | -88.3% | +672.2% | -94.7% | +347.7% | -146.2% | – | -502.0% | – | -100.1% | – | |
| – | -1,047.9% | – | -183.9% | – | -246.6% | – | -142.4% | – | -125.7% | – | – | – | |
| – | – | – | – | – | – | – | -134.5% | – | -12.8% | +622.5% | -321.5% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.